Certara (NASDAQ:CERT) Given New $18.00 Price Target at KeyCorp

Certara (NASDAQ:CERT) had its price target boosted by KeyCorp from $15.00 to $18.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Barclays dropped their price target on Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Robert W. Baird upped their price objective on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. Finally, Stephens reiterated an “overweight” rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Stock Performance

NASDAQ:CERT opened at $14.15 on Wednesday. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -70.75, a PEG ratio of 9.29 and a beta of 1.64. Certara has a 1 year low of $8.64 and a 1 year high of $17.94. The stock’s 50 day simple moving average is $11.62 and its two-hundred day simple moving average is $11.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Hedge Funds Weigh In On Certara

A number of large investors have recently bought and sold shares of CERT. Vanguard Group Inc. lifted its position in shares of Certara by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock worth $132,455,000 after purchasing an additional 38,068 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its stake in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Teacher Retirement System of Texas lifted its holdings in Certara by 13.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after buying an additional 557,348 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Certara by 4.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company’s stock valued at $43,494,000 after buying an additional 182,042 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock worth $40,668,000 after acquiring an additional 1,487,998 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.